TB-500 (5mg)
TB-500 is a synthetic peptide corresponding to the active region of thymosin beta-4 (Tβ4), studied for tissue repair and anti-inflammatory activity. Research-use literature describes a loading phase of 2 mg, twice weekly and maintenance of 2 mg, once weekly.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full TB-500 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
TB-500 represents the N-terminal active fragment of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. This region is responsible for its actin-binding and cell migration properties. Preclinical studies show that TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Recent metabolic studies suggest it may act as a prodrug, breaking down into an active pentapeptide metabolite.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
- Loading (Wks 1–4): 2 mg twice weekly (4 mg/week).
- Maintenance (Wks 5–8): 2 mg once weekly.
- Easy measurement: At 2.5 mg/mL, 2 mg = 80 units (0.80 mL) on a U-100 syringe.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, use within 28 days.
Literature-reported ranges (2.0 mL = 2.5 mg/mL)
Route: Subcutaneous | Frequency: 2×/week (loading) → 1×/week
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 (loading) | 2 mg | 80 Units (0.80 mL) |
| Weeks 5–8 (maintenance) | 2 mg | 80 Units (0.80 mL) |
Loading: twice weekly (e.g., Monday/Thursday) for 4 weeks. Maintenance: once weekly. There is no validated human dosing for TB-500.
Related compounds
Reconstitution Steps
- Draw 2.0 mL of bacteriostatic water.
- Inject slowly down the vial wall; avoid foaming.
- Swirl gently until fully dissolved — do not shake.
- Note the reconstitution date and refrigerate at 2–8 °C.
Protocol Overview
- Literature-reported scope: Tissue repair, anti-inflammatory activity and angiogenesis (mostly preclinical data).
- Literature-described schedule: Loading 2 mg × 2/week for 4 weeks, maintenance 2 mg × 1/week.
- Doses per vial: 2.5 × 2 mg.
Dosing Protocol
- Loading (Weeks 1–4): 2 mg × 2/week = 4 mg/week.
- Maintenance (Weeks 5–8): 2 mg × 1/week.
- Literature-described break: 4–6 weeks after the cycle.
- There is no validated human dosing — research context only.
- Break between cycles: After the 8-week cycle, the literature describes a 4–6 week break.
Washout & Cycle Restart
When can I restart?
After the 8-week cycle, the literature describes a 4–6 week break.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C in dry, dark conditions.
- Reconstituted: 2–8 °C; use within 28 days.
- Avoid freeze-thaw cycles.
Important Notes
- Regulatory Note: TB‑500 is prohibited by WADA for athletic use and is not approved by the FDA for human administration.
Potential Benefits & Side Effects
Potential Benefits:
- Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration.
- May reduce inflammation and fibrosis via thymosin pathways in animal models.
- Generally well-tolerated in veterinary studies; potential for mild injection site reactions.
- Human safety data is limited; large-scale clinical trials have not been completed.
Potential Side Effects:
- Injection site reactions (redness, itching).
- Transient fatigue or weakness (initial days).
- Headache (rare).
- Dizziness or flushing sensation (rare).
- Human data is preliminary.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007References
- FASEB Journal — Biological activities of thymosin β4 — identification of the TB-500 fragment
View Source - Journal of Chromatography A — Doping control analysis of TB-500 in biological samples
View Source - J. Investigative Dermatology — Thymosin β4 accelerates wound healing (preclinical model)
View Source - WADA Prohibited List — TB-500 as a prohibited substance in competitive sport
View Source - J. Chromatography B (2024) — Quantification of TB-500 metabolites and activity testing (prodrug hypothesis)
View Source
Recommended Supplements
Curcumin (Turmeric Extract)
Collagen Peptides
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →